News Wire

Reducing excessive medical costs associated with high hospital readmission rates is a pillar of health care reform. From 2007 to 2011, as many as 19% of patients in the U.S. returned to hospitals less than a month after discharge, accounting for an estimated $15 million in preventable hospitalization…
Better coordination between hospitals and post-acute care facilities could reduce patient readmission to hospitals and mortality rates, according to a new study of risk factors conducted by researchers at the University of Colorado’s Anschutz School of Medicine. In a review of more than 3,200 hospitalizations…
It can be difficult to quantify the exact economic burden of Clostridium difficile infections on hospitals and the health system as a whole, but a recent study has put a dollar amount on the cost of C. difficile-associated diarrhea that is not only big but also likely to be underestimated, according…
The FDA has approved secukinumab (Cosentyx, Novartis) for the treatment of adults with two new indications: active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are life-long painful and debilitating inflammatory diseases that affect the joints and/or spine. If not treated…
A new drug application (NDA) has been submitted to the FDA for the approval of oral once-daily baricitinib (Eli Lilly/Incite Corporation) for the treatment of moderately to severely active rheumatoid arthritis (RA). Baricitinib is the only once-daily oral selective Janus kinase-1 (JAK1) and JAK2 inhibitor…
Glioblastoma multiforme (GBM) is a disease with some of the highest unmet needs in oncology, with patients having a median overall survival (OS) of between one and two years. The lack of effective therapies is primarily due to the inability of drugs to penetrate the blood–brain barrier. The GBM market…
The FDA has informed Heron Therapeutics, Inc., that it has not yet completed its review of the new drug application for granisetron injection, extended release (Sustol), and would not be taking action by the Prescription Drug User Fee Act goal date of January 17, 2016. The agency now anticipates taking…
The largest analysis of breast cancer cell function to date has suggested dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations. The results of the study, which was conducted by researchers in New York City and Toronto, were published online in Cell. “This…
One person has been left brain-dead and five others are in serious condition after participating in a clinical trial in France of an experimental painkiller, Reuters reports. The new drug, made by a Portuguese company, works by targeting the body’s pain-controlling endocannabinoid system, which is…
The FDA has issued a complete response letter to the new drug application (NDA) for drisapersen (Kyndrisa, BioMarin Pharmaceutical Inc.) for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The FDA issues complete response letters to indicate that an application…
A new industry survey from HealthLeaders Media outlines the top challenges providers are facing in the transition to value-based care. This transition is significant both for the magnitude of the task and for health care leaders’ reluctance to make a full commitment to change, the survey results suggest.…
At least 250 people, mostly in the U.S., developed life-threatening “superbug” infections linked to contaminated medical scopes during the past three years — more than previously estimated by federal regulators, according to a new report from the Senate Health, Education, Labor, and Pensions (HELP)…
A new report from business intelligence provider GBI Research states that six pancreatic cancer drugs are expected to gain approval by 2021, all of which have demonstrated significant improvement in progression-free survival and/or overall survival in clinical trials. Market growth is anticipated in…
A long-term follow-up study of chronic heart failure patients treated with cardiac contractility modulation (CCM) has been published online in the International Journal of Cardiology. Those receiving CCM experienced significantly improved long-term survival compared with matched patients who did not…
Positive results from a phase 2 study of enzalutamide (Xtandi, Astellas US/Medivation, Inc.) compared with bicalutamide in patients with metastatic castration-resistant prostate cancer have been published online in Lancet Oncology. The TERRAIN trial enrolled 375 patients in North America and Europe.…

Pages